From Growth factor shows promise for Phelan-McDermid syndrome
"Last week, a separate set of researchers announced that the drug appears to be safe and effective in a trial of 53 adolescents and adults with Rett syndrome."
The inference is that IGF-1 was the drug being used instead of NNZ-2566. Only later on do you learn that:
"The Rett trial uses a modified form of IGF-1 that includes only the first three amino acids, but which may induce production of the full-length form in the brain"
I have noticed in a number of articles IGF-1 was being hyped and NNZ-2566 downplayed or not mentioned (as in the above announcement). To me IGF-1 is a competitor.
- Forums
- ASX - By Stock
- Wider autism efficacy potential for nnz-2566
NEU
neuren pharmaceuticals limited
Add to My Watchlist
1.00%
!
$13.88

From Growth factor shows promise for Phelan-McDermid syndrome...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.88 |
Change
-0.140(1.00%) |
Mkt cap ! $1.727B |
Open | High | Low | Value | Volume |
$13.90 | $14.21 | $13.64 | $4.590M | 329.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 600 | $13.85 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.96 | 2894 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 600 | 13.850 |
1 | 2500 | 13.770 |
1 | 581 | 13.760 |
1 | 377 | 13.750 |
1 | 2500 | 13.700 |
Price($) | Vol. | No. |
---|---|---|
13.960 | 2894 | 1 |
14.000 | 2800 | 2 |
14.160 | 2500 | 1 |
14.180 | 1500 | 1 |
14.200 | 2500 | 1 |
Last trade - 16.10pm 08/07/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |